Volcano touts record Q4 sales

January 8, 2013 by Arezu Sarvestani

Medical device company Volcano (NSDQ:VOLC) unveiled a preliminary look at its Q4 and 2012 financial results, saying it expects record sales of more than $102 million for the quarter.

If it hits that target, Volcano's full-year sales will amount to nearly $392 million, a jump of about 10% over 2011.

Sales were partly driven by a 42% increase in disposable fractional flow reserve products, a segment expected to be worth about $27.2 million in sales during the 3 months ended December 31.

Sign up to get our free newsletters delivered right to your inbox.

Volcano develops products in a self-defined region it calls "precision-guided therapy," meaning a combination of imaging and therapeutic systems that are integrated into a single platform.

"We're really the only pure-play in this segment," president & CEO Scott Huennekens told an audience today in San Francisco. "This year, 2013, is going to be the 1st year that this market segment is over $1 billion in revenue by our projections and outside consultants, analysts, et cetera."

Volcano has put its money on integrated imaging and therapeutics systems and disposables for those systems, where Huennekens said the company has a "winning strategy."

Permalink